Hamdard Looks To Chart Out New Growth Strategies For Medicine Vertical
Hamdard Laboratories has lined up an ambitious expansion plan for its medicine division as it aims to clock over Rs 1,000 crore turnover from the vertical in the next five years, a top company official has said.
The Delhi-based firm, which currently generates revenues of around Rs 400 crore from the business vertical, has roped in global professional services organisation EY to formulate strategies to chart out its future course of action.
“We're market leaders in the categories where we currently operate so what we are now trying to do is that we have brought in EY to revamp our go to the market strategy,” Hamdard Laboratories (Medicine Division) Chairman Abdul Majeed told PTI in an interview.
The company, which has around 450 products—including patented ones—is getting its house in order as it looks to expand brand categories and enter smaller towns and rural areas, he added.
When asked how EY would help the company, Majeed said: “The EY is helping us formulate a go-to-the market strategy which will propel us from a current turnover of around Rs 400 crore to over Rs 1,000 crore in the next five years.”
EY will also come out with the details on how the company can go about the process of brand extensions, besides guiding its foray into lucrative markets in the country as well as abroad, he said.
Based on EY findings and strategies, the basic blueprint is expected to come in the next 2-3 months, the company would allocate resources for future growth.
The company, a leading producer of Unani system of medicines in the country, can pump in around Rs 375 crore to come up with a new facility to roll out products with global standards, he said.
“We're looking at Delhi/NCR, Haryana, Uttarakhand and Himachal Pradesh to set up this plant,” Majeed said.
The company's medicine division currently rolls out products from three plants in Manesar (Haryana), Okhla (Delhi) and Ghaziabad (Uttar Pradesh).
It also has Unani medicine clinics at various places in Uttar Pradesh, Delhi, Telangana, Karnataka, among others.
Some of the well-known brands of the company include Safi and Joshina.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
